New Anticancer 4-Aryldihydropyrimidinone-5-Carboxylates Targeting Hsp90

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Molecular Pharmacology

Background:

• Heat shock protein 90 (Hsp90) is overexpressed in cancers, correlating with poor prognosis and promoting tumor progression.
• Existing Hsp90 inhibitors have shown limited clinical success, necessitating the development of new chemical scaffolds.
• Targeting Hsp90 is a promising strategy in cancer treatment, but requires novel inhibitors.

Purpose of the Study:

• To design and synthesize novel 4-aryldihydropyrimidinone-5-carboxylate derivatives as potential Hsp90 inhibitors.
• To evaluate the structure-activity relationship (SAR) of these compounds in human breast cancer models.
• To identify promising hit compounds for further preclinical development.

Main Methods:

• Virtual screening identified a hit compound mimicking geldanamycin binding to the Hsp90 ATP site.
• Synthesis of a series of substituted 4-aryldihydropyrimidinone-5-carboxylate derivatives (5a-n).
• Evaluation of Hsp90 inhibition, cell growth inhibition, colony formation, and early ADME profiling in breast cancer cell lines.

Main Results:

• Compound 5d demonstrated potent inhibition of colony formation in breast cancer cell lines.
• Compound 5d effectively inhibited Hsp90 activity.
• Early ADME profiling indicated moderate metabolic stability and solubility for compound 5d, with no hERG channel inhibition.

Conclusions:

• Compound 5d is a promising hit compound with potent anti-cancer activity and Hsp90 inhibitory effects.
• The 4-aryldihydropyrimidinone-5-carboxylate scaffold represents a viable starting point for developing novel Hsp90 inhibitors.
• Further optimization of compound 5d is warranted for potential cancer therapeutic applications.